Galectin Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Belapectin demonstrated significant reduction in new esophageal varices and improvement in key fibrosis biomarkers in advanced MASH cirrhosis patients with portal hypertension. The therapy showed a strong safety profile and is uniquely positioned to address an unmet need, with regulatory discussions ongoing.
Fiscal Year 2025
-
The meeting saw the re-election of all directors, approval of executive compensation, and ratification of the auditor. Key updates included strong Navigate trial results for belapectin, ongoing FDA engagement, and strategic planning for future growth.
-
Presenters detailed promising results for belapectin in preventing varices and reducing fibrosis in MASH cirrhosis with portal hypertension, highlighting its favorable safety profile and potential as a first-in-class therapy. Regulatory and partnership discussions are ongoing.
-
Belapectin demonstrated a significant reduction in varices incidence in NASH cirrhosis patients with portal hypertension, especially in those completing the full protocol, and showed favorable biomarker and safety profiles. Regulatory discussions and partnership opportunities are underway.
-
Belapectin demonstrated a significant reduction in new esophageal varices and disease progression in advanced MASH cirrhosis patients with portal hypertension, especially in those without baseline varices, and showed a favorable safety profile. NAVIGATE results validate earlier findings and highlight a major market opportunity.
Fiscal Year 2024
-
Belapectin, a galectin-3 inhibitor, is advancing through pivotal trials for MASH cirrhosis and oncology, with promising safety and efficacy data. The NAVIGATE trial's interim results in Q4 could position it as the first FDA-approved therapy for cirrhosis with portal hypertension.
-
Belapectin, a galectin-3 inhibitor, is advancing in late-stage trials for NASH cirrhosis and portal hypertension, with promising efficacy and safety data, and a novel, FDA-endorsed clinical endpoint. The program targets a vast unmet need and multi-billion dollar market.